Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Protein Implicated in Aberrant B-cell Survival in Transplant Disease

By BiotechDaily International staff writers
Posted on 27 Aug 2012
Ex vivo study finds that B-cells from patients with chronic graft vs. host disease (cGVHD) are in a heightened metabolic state and are resistant to apoptosis compared to patients without cGVHD, and leads to identification of a key candidate target for development of more effective drug therapies.

The research team, primarily from University of North Carolina’s Lineberger Comprehensive Cancer Center (UNC Lineberger; Chapel Hill, NC, USA), performed ex vivo analyses of peripheral B cells from 51 patients who either had or did not have active cGVHD and were greater than one year from the time of allogeneic hematopoietic stem cell (HSCT) transplantation. In addition to the finding of the aberrantly sustained activation of the B-cells from patients with cGVHD, an investigation into the mechanisms involved in this process led to the implication of a mechanistic link between this abnormal B-cell survival and the TNF family member signaling protein called BAFF, thus identifying BAFF as having an important role in the pathogenesis of cGVHD.

For patients who received bone marrow or stem cells, it is estimated that 40%-70% may experience chronic GVHD.

“Steroids are currently our only standard treatment for chronic GVHD and they are often not effective,” noted senior author Stefanie Sarantopoulos, MD, PhD, assistant professor in the division of hematology/oncology and the departments of microbiology and immunology at the UNC School of Medicine. This study offers BAFF and the BAFF-mediated signaling pathways that contribute to this “revved up” B-cell activity as potentially suitable sources of novel therapeutic targets for chronic GVHD patients.

The study was published August 15, 2012, in the journal Blood.

Related Links:

University of North Carolina’s Lineberger Comprehensive Cancer Center




Channels

Genomics/Proteomics

view channel
Image: Typical antibodies (left) unfold in the harsh environment of the cell. Camelid antibodies (right) are smaller and more stable (Photo courtesy of the Washington University School of Medicine).

Double Targeting Approach Increases Potential for Cancer Treatment with Oncolytic Viruses

Cancer researchers have used a double targeting approach to direct oncolytic viruses specifically to tumor cells where they reproduce until the cancer cells burst, releasing more viruses to infect and... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.